Skip to main content
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 2003 Nov;134(2):365. doi: 10.1046/j.1365-2249.2003.02309.x

Corrigendum

PMCID: PMC1808875

Del Zotto B, Mumulo G, Pronio AM, Montesani C, Tersigni & Boirivant M. TGF-β1 production in inflammatory bowel disease: differing production patterns in Crohn's disease and ulcerative colitis. Clin Exp Immunol 2003; 134:120–126.

In Table 1 of the above article, the units in the column headings for TGF-β1, IFN-γ and IL-5 were incorrectly given as ng/ml, when they should have read pg/ml. The correct version of Table 1 is shown below. The authors wish to apologize for any confusion caused.

Table 1.

Production of TGF-β, IFN-γ and IL-5 by LPMC isolated from CD and UC involved tissue and small bowel and colonic controls. Cells were cultured for 72 h in medium containing 1% Nutridoma

TGF-β1 (pg/ml) TGF-γ (pg/ml) IL-5 (pg/ml)



Unstim median (range) αCD2+ αCD28 median (range) Unstim median (range) αCD2+ αCD28 median (range) Unstim median (range) αCD2+ αCD28 median (range)
Small bowel controls 3·65 211 ND 1651 ND 1·36
(n = 4) (ND-7) (58–554) (429–4562) (ND-2)
Small bowel CD 3 32 ND 5000 ND ND
(n = 3) (ND-15) (27–33) (3513–10 220) (ND-28)
Colon controls 3·33 38 ND 3105 ND 0·8
(n = 5) (ND-13) (14–61) (2467–3515) (ND-23)
UC ND 95 8·9 2404 ND 179·6
(n = 4) (50–249) (ND-29) (1604–10 400) (104–389)

ND = not detectable.


Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES